Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced key changes to its executive team that will strengthen its leadership and sharpen the Company's focus ...

Modern Litho, a leading full-service publication and commercial printer, today announces a significant expansion of its direct mail capabilities at its St. Louis location. The company has recently ...

she let Master Welles (when he could get a word in edgewise) explain to her what the world was like. Indeed, she was so zestfully contemporary with each new thing it was hard for me to realize she ...

Makar Sankrant Day. January 14, 1761. An auspicious day for Hindus across India. But one of the blackest days in the ...

January 13, 2025--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

Additionally, Edgewise is set to report significant data from its Phase 2 studies in Duchenne muscular dystrophy in the first half of 2025, which will further guide their Phase 3 planning.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s shares closed yesterday at $25.33. Discover ...